The Latest
-
Profile
Jumping into pharma with big plans at a small company
SpringWorks Therapeutics' chief medical officer on the ambition that drives him and his company to develop treatments for cancer patients.
-
Sponsored by ClinicalMind
3 things medical communications can learn from sales training experts
Medical communications is moving toward more modern approaches that can make critical information more engaging and better able to "stick".
-
Retrieved from Diego Camargo/PharmaVoice on May 17, 2022
Podcast
Woman of the Week: Sparrow Pharmaceuticals' Jamie MacPherson
The vice president of regulatory affairs and quality on embracing leadership challenges in drug development.
-
Q&A
Biotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach
Using gene editing, CEO Josh Lehrer says the company is poised to ‘offer a cure’ to a long list of diseases.
-
Q&A
BriOri BioTech sets the stage for the comeback of Vioxx
With a topical pain-relieving ointment in development, the emerging biotech is aiming to give the tarnished NSAID a new life.
-
After 40 years, researchers discover new frontiers in the fight against HIV
Medical advances in the last two decades may now provide scientists with the right toolbox to target the long-elusive virus.
-
Are digital DCTs the answer for rare diseases?
How data from EHRs is helping to identify, diagnose and recruit patients to decentralized clinical trials.
-
Sophia Sharp-Donaldson, executive director, Global Strategic Sourcing and Procurement, Kite Pharma and one of this year's HBA Luminary honorees.
OpinionWhy 'soft' skills matter in the new era of leadership
Standout leaders honored by the Healthcare Businesswomen's Association discuss the rising value of the interpersonal approach.
-
In the hot pharma talent market, execs battle these recruitment misconceptions
One of the top recruiting firms in life sciences weighs in on how companies can attract the next wave of rising stars.
-
Profile
With the shine of amyloid fading, tau is a rising star in Alzheimer's
The tau theory in Alzheimer's is being put to the test with phase 3 trial results due later this month from TauRx Pharmaceuticals.
-
It's time to acknowledge access as a prescribing barrier
A new survey reveals how red tape limits patient access to doctor-preferred specialty drugs.
-
Podcast
Woman of the Week: AiCure's Michelle Marlborough
As chief product officer at AiCure, Michelle Marlborough is focused on solving tough patient challenges through technology.
-
Where hope and uncertainty meet: A cutting-edge cancer developer's winding road
Replimune is on the precipice of a new kind of cancer treatment, but its CEO knows something about ambiguity.
-
FDA draft guidance may turn diversity in clinical trials from nice-to-have into a must-have
New guidance from the FDA will ‘up the ante’ for diversity considerations. Here’s how your company can prepare.
-
Q&A
Biotech Spotlight: Everest Medicines takes aim at unmet needs in Asia
With a multi-pronged business strategy, Everest Medicines is positioning itself as a ‘rising force’ in Asian biotech.
-
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
Ultra-sensitive tests bring biomarkers into the drug development forefront
An agreement between the biomarker assay maker Quanterix and pharma giant Eli Lilly could help discover new ways to treat Alzheimer's.
-
Pharma's solution to the digital advertising dilemma? Storytelling
Peter Shin, vice president of Client Services at Sonic Health, says quality storytelling, rather than trendy content, is central to a digital advertising strategy.
-
Profile
Breaking new ground: Longhorn's trailblazing effort to develop a universal flu vaccine
After years of success with their diagnostic platform for COVID-19, tuberculosis and the flu, the family funded company is shifting priorities back to the vaccine market.
-
Podcast
Woman of the Week: Amgen's Dr. Jane Parnes
As executive medical director, early development at Amgen, Dr. Jane Parnes has helped guide clinical research for upwards of 30 of the company’s investigational molecules, including the newly approved Tezspire for severe asthma — one of her career highlights.
-
Profile
Bayer executive makes strides toward a finish line for rare cancers
Bayer's SVP and general manager of U.S. oncology completed the Boston Marathon to honor his brother and bring attention to rare cancers.
-
Profile
From cancer survivor to clinical trial innovator
How Alicia Staley is using her insights as a three-time cancer survivor to drive clinical trial improvements at Medidata.
-
A nuclear threat spurs France's Medesis to advance radiation therapy
In the event of a nuclear event — intentional or accidental — rapid and widespread deployment of effective treatments is paramount.
-
Q&A
One company's failed drug is this company's 'jewel'
Dr. Thomas Bock, CEO of Notable, is helping the company develop a ‘new class’ of predictive precision medicines in oncology.
-
The 'innovation gap' haunts Big Pharma, and the race is on for the next blockbusters
The next big innovation wave is out there, and as pharmas expect massive losses without enough internal R&D to fill those shoes, smaller biotechs beckon.
-
Q&A
How an open platform can shake up the drug development process
TetraScience’s Alan Millar shares why pharma is rethinking data integration in the race to be faster, better and more effective.
-
Profile
Laura Randa's aim to break down mental healthcare barriers for disabled patients
Despite the proliferation of mental health apps, many aren’t accessible for people with disabilities. The CEO of Toivoa plans to change that.